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In liver cancer, miR-155 up-regulation can regulate cancer-cell invasion. However, whether miR-155
expression is associated with liver cancer stem cells (CSCs) remains unknown. Here, we show that
miR-155 expression is up-regulated in tumor spheres. Knock-down of miR-155 resulted in suppres-
sion of tumor sphere formation, through a decrease in the proportion of CD90+ and CD133+ CSCs and
in the expression of Oct4, whereas miR-155 overexpression had the opposite effect. TP53INP1 was
determined to be involved in the CSCs-like properties that were regulated by miR-155. Thus, miR-
155 may play an important role in promoting the generation of stem cell-like cells and their self-
renewal by targeting the gene TP53INP1.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is the sixth most prevalent
cancer and the third most frequent cause of cancer-related death
[1]. Although surgical resection have signiﬁcantly improved sur-
vival in patients at very early stage, however, long-term survival
remains unsatisfactory and development of tumor recurrence is
the main cause of long-term death [2]. Therefore, we urgently need
to understand the molecular mechanisms of the occurrence of liver
cancer.
Cancer stem cells (CSCs), also termed as cancer initiating cells, is
a small set of self-renewing cells are believed to initiate and main-
tain cancers [3]. Liver CSCs dictate a hierarchical organization that
is shared in both organogenesis and tumorigenesis [4]. CSCs in liver
cancer cells can be enriched by sorting cells with speciﬁc surface
markers such as CD90 [5], CD133 [6] or detection of side popula-
tion (SP) phenotype by Hoechst33342 exclusion [7] or by sphere
formation using serum-free culture medium [8]. We have recently
reported that spheres cultured in serum-free culture medium
(SFM) can up-regulated the mRNA and protein levels of CD90,
CD133 and the stem cell-speciﬁc transcription factor Oct4 [9].
MicroRNAs (miRNAs) are a class of endogenous 22 nt non-
coding RNAs can play important regulatory roles by targeting
mRNAs for cleavage or translational repression in animals andplants [10]. Recently, increasing studies have revealed that many
miRNAs play crucial roles in tumorigenesis [11,12], including CSCs
[13,14]. Recent data suggest that there are miRNAs regulate stem-
like traits in liver cancer cells, including miR-214 [15], miR-148a
[16], miR-612 [17]. It has been reported that miR-155 was up-reg-
ulated in many cancers and plays an important role in tumorigen-
esis [18,19], including HCC [20]. However, its molecular roles in
stem-like traits remain largely unknown.
Herein, we report that miR-155 play an important role in the
acquisition of CSC phenotype. We demonstrated that the down-
regulation of miR-155 can decreased the subpopulation of CD90+
and CD133+ cells, the formation of spheres, and suppressed the
expression of Oct4. Additionally, we also found that TP53INP1
(Tumor Protein 53-Induced Nuclear Protein 1) could regulated
the CSC phenotype, which was regulated by miR-155. These ﬁnd-
ings suggest that miR-155 regulates the acquisition of stemness
in liver cancer cells and it may serve as a potential target in future
liver cancer therapy.
2. Methods
2.1. Cell lines and culture
The human liver cancer cell line MHCC-97H was purchased
from the Liver Cancer Institute, Zhongshan Hospital, Fudan Univer-
sity, Shanghai, China. The human liver cancer cell line, HepG2, was
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hai, China. The above cell lines were maintained in Dulbecco’s
modiﬁed Eagle medium (DMEM; Gibco) supplemented with 10%
fetal bovine serum (FBS; Gibco) and 100 units/ml penicillin and
100 lg/ml streptomycin, and the cells were maintained at 37 C
in 5% CO2. CSCs sphere formation were performed in serum-free
culture medium (SFM), SFM was composed of DMEM/F12 (Gibco),
10 ng/ml basic ﬁbroblast growth factor (bFGF; PeproTech), 20 ng/
ml EGF (PeproTech) and 20 ll/ml B27 supplement (Life
Technologies).
2.2. RNA extraction and real-time RT–PCR
Total RNA was extracted from the cultured cells using Trizol
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instruc-
tions. For miRNA analysis, real-time PCR was performed using the
Hairpin-it™ miRNAs RT-PCR Quantitation Kit (GenePharma,
Shanghai, China). All miRNA data are expressed relative to the U6
small nuclear RNA and analyzed using the 2DDCt method. For
the analysis of mRNA expression, complementary cDNA synthesis
was performed using the PrimeScript™ RT Reagent Kit with gDNA
Eraser (Takara), Real-time PCR was conducted using SYBR Premix
ExTaq (Takara) under standard conditions according to the manu-
facturer’s instructions. Real-time PCR was performed on the CFX96
Real-Time PCR Detection System (Bio-Rad, USA). GAPDH was the
internal control, and analyzed using the 2DDCt method. The prim-
ers are listed in Supplementary Data Table S2.
2.3. Cell transfection
MiR-155 agomir, small interfering RNAs (siRNA) and negative
control (NC) were designed and synthesized by GenePharma
(Shanghai, China). The cells were transfected using siRNA-Mate™
(GenePharma) according to the manufacturer’s protocol. Brieﬂy,
the cells were seeded at 2–3  105 cells per well and grown to
30–50% conﬂuence. Transfection complexes were prepared accord-
ing to the instructions and were added directly to the cells. The
miR-155 agomir and negative control were used at a ﬁnal concen-
tration of 50 nM, and the TP53INP1 siRNA and negative control
were used at a ﬁnal concentration of 100 nM. RT-PCR was used
to assess the miR-155 levels after incubation for 24–48 h, andWes-
tern blot was used to determine the level of protein expression
after incubation for 48 h. The sequence of the agomir and small
siRNA are listed in Supplementary Data Table S3.
2.4. Establishment of the miR-155 stable knock-down cell line
To establish stable transduction, we purchased a lentiviral vec-
tor containing the anti-sense of miR-155 or miR-control sequence
from GeneChem (Shanghai, China). Transfection was performed
using polybrene (GeneChem) according to the manufacturer’s
instruction. Brieﬂy, the cells were seeded at 2  105 cells per well
and grown to 20–40% conﬂuence, then the cells were transfected
at a multiplicity of infection (MOI) of 40. After 72–96 h, the cells
were veriﬁed by ﬂuorescence microscopy and qRT-PCR.
2.5. Flow cytometric analysis
Up to 1  106 cells were resuspended in 100 ll PBS containing
20 ll FcR Blocking Reagent (Miltenyi Biotec) and placed on ice
for 10 min to block the Fc receptors. After incubating with the
anti-human antibodies, PE-CD90 and PE-CD133 (Miltenyi Biotec),
for 30 min on ice in the dark, the cells were washed with 1 ml
ice-cold PBS for two times. The collected cells were resuspended
in 300 ll PBS and were detected using a FACSCanto II ﬂowcytometer (BD Biosciences). Isotype-matched mouse antibodies
served as controls.
2.6. Cell sphere formation assay
Single cells (1  103) were plated in a 24-well ultra-low attach-
ment plate (Corning, Corning, NY) in the serum-free culture med-
ium (SFM) described above. After 14 days of culture, the number
of tumor spheres formed (diameter > 50 lm) was counted under
an inverted microscope.
2.7. Protein extraction and Western blotting
Total protein was extracted from the cells using RIPA lysis buf-
fer and the protein concentration was determined using a BCA Kit
(Pierce). The proteins were separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and transferred to polyvinyli-
dene diﬂuoride membranes (Millipore). The membranes were
incubated overnight at 4 C with primary antibodies after blocked
with 5% defatted milk. The membranes were subsequently washed
using Tris-buffered saline with 0.1% Tween (TBST) and incubated
with horseradish peroxidase-linked secondary antibody for 1 h.
Blots were visualized using enhanced chemiluminescence reagent
(Engreen). The following antibodies were used: b-actin (YT0099,
Immunoway), anti-TP53INP1 (AB62004a; SangonBiotech, Shang-
hai, China).
2.8. Statistical analysis
The SPSS 21 software was used for statistical analysis. All data
were acquired from at least three independent experiments and
are presented as the mean ± S.D. The Student’s t-test was used
for comparisons between two independent groups. P < 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Up-regulation of miR-155 is associated with the population of
CSCs
Many studies conﬁrmed that the spheres cultured in serum-free
culture medium (SFM) are highly enriched for cancer stem cells. To
investigate whether miR-155 is associated with the phenotype of
CSCs, we cultured MHCC-97H cells in SFM. After 2 weeks, spheres
formation was observed under an inverted microscope (Fig. 1A). It
has been reported that the CD90+ cells, fromMHCC-97L/H cell lines
displayed CSC phenotype [5]. Colony formation assays, and in vivo
SCID mice tumorigenesis experiments were used to characterize
CSCs in CD133+ MHCC-97H cells. Tumor nodules from the
CD133+ cells isolated from MHCC97H cells appeared after 7 weeks
from 1  104 inoculated cells, While tumor nodules from the
CD133 cells appeared after 7 weeks need from 2  105 inoculated
cells (Supplementary Data Fig. A and Table S1). Additionally, the
CD133+ cells showed a higher clonogenic capacity than CD133
cells (Supplementary Data Fig. B). So in the subsequent experi-
ments we chose CD90 and CD133 as the surface markers of CSCs.
The population of CD90+ and CD133+ cells were measured by ﬂow
cytometric analysis, and we found that the percentage of CD90+
and CD133+ cells were increased in spheres compared to the
parental cells (Fig. 1B). The mRNA levels of CD90 and CD133 were
also increased in sphere cells, detected by qRT-PCR (Fig. 1C). It has
been reported that transcription factor Oct4 is a critical player in
maintaining the self-renewal state of liver cancer stem cells [21],
and we found that the expression of Oct4 mRNA was signiﬁcantly
higher in spheres than in parental cells (Fig. 1D). These data
Fig. 1. Up-regulation of miR-155 is associated with CSCs. (A) Representative image of tumor sphere generated after 14 days of single-cell cultures in SFM. Scale bar: 50 lm.
(B) A ﬂow cytometry histogram analysis shows the enrichment of CD90 and CD133 expression in spheres as compared to the adherent parental cells, P < 0.05. qPCR analysis
was performed for CD90, CD133 (C) and stem cell-associated gene Oct4 (D) in spheres versus adherent parental cells. (E) The expression of miR-155 was higher in spheres
compared with parental cells, detected by qPCR, ⁄P < 0.05.
Fig. 2. Inhibition of stem-like cell phenotypes by stable knockdown of miR-155 in MHCC-97H cells. (A) qPCR analysis of miR-155 expression in MHCC-97H cells lacking miR-
155. (B) Flow cytometry analysis of CD133+ and CD90+ cells distribution in anti-NC and anti-miR-155 cells, P < 0.05. (C and D) The relative mRNA levels of CD90, CD133 and
Oct4 were detected by qPCR assay. (E) anti-miR-155 cells were able to generate a decreased number of spheres as compared with anti-NC cells. Scale bar: 100 lm, ⁄P < 0.05.
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for CSCs by spheres formation.
We furthered our study to test the expression of miR-155 in
sphere cells and parental cells by qPCR. The result demonstrated
that miR-155 expression was enriched in the sphere cells as com-
pared with the parental cells (Fig. 1E). The result prompted us to
study whether miR-155 play an important role in the stem-like
phenotype acquisition and self-renewal.3.2. Silencing of miR-155 decreased population of CSCs
To examine the effects of miR-155 on CSC phenotype in liver
cancer cells, we established a lentivirus-mediated stable miR-155
down-regulation cell line (anti-miR-155) or negative control cell
line (anti-NC) using MHCC-97H, and the inhibition of miR-155
was detected by qPCR (Fig. 2A). We ﬁrst measured the proportion
of CD90+ or CD133+ cells in anti-miR-155 cells and negative control
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155 cells was signiﬁcantly less than in negative control group
(Fig. 2B). Moreover, the relative mRNA expression of CD90 and
CD133 in anti-miR-155 cells and anti-NC cells were also measured.
The relative mRNA levels of CD90 and CD133 in anti-miR-155 cells
were signiﬁcantly decreased as compared to control groups,
assessed by real time RT-PCR analysis (Fig. 2C). Additionally, the
mRNA level of Oct4 was also decreased in anti-miR-155 cells com-
pared to the anti-NC cells (Fig. 2D). To further demonstrate the
results above, we performed the sphere-formation assay, and the
result indicated that the sphere number in anti-miR-155 cells
was signiﬁcantly smaller than anti-NC cells (Fig. 2E). These results
suggested that suppression of miR-155 could decrease the CSC pro-
portion and weaken CSCs self-renewal in liver cancer cells.
To further conﬁrm the role of miR-155 in regulating CSC pheno-
type, miR-155 agomir or negative control was transfected into
established anti-miR-155 cells (anti-miR-155-agomir or anti-
miR-155-NC), and miR-155 re-expression was detected by qPCR
(Fig. 3A). As compared to the negative control groups, forced re-
expression of miR-155 increased the proportion of CD90+ and
CD133+ cells (Fig. 3B), and the mRNA expression of CD90, CD133
and Oct4 (Fig. 3C). Additionally, the sphere-formation ability was
increased in anti-miR-155-agomir group compared to the anti-
miR-155-NC group (Fig. 3D).
3.3. Overexpression of miR-155 increased CD90/CD133/Oct4
expression
To further examine the role of miR-155 in regulating CSC phe-
notype, miR-155 was transiently up-regulated by transfection of
agomir or NC in both HepG2 and MHCC-97H cells, and the overex-
pression of miR-155 was conﬁrmed by qPCR (Fig. 4A). We exam-
ined liver cancer stem cell markers, CD90, CD133 and Oct4 in
both miR-155-agomir-HepG2 and miR-155-agomir-MHCC-97HFig. 3. Induction stem-like cell phenotypes by re-expression of miR-155 in anti-miR
transfected anti-miR-155 cells with miR-155 agomir (anti-miR-155-agomir), detected by
after transfected anti-miR-155 cells with miR-155 agomir, P < 0.05. (C) The expression lev
anti-miR-155-agomir cells generated a greater number of spheres as compared with ancells by qPCR, and found that these cells showed increased CSC
markers expression compared to the miR-155-NC-HepG2 and
miR-155-NC-MHCC-97H cells, respectively (Fig. 4C and D), sug-
gesting that the over-expression of miR-155 increased the cancer
stem-like cell stem-ness.
3.4. Down-regulation of TP53INP1 promotes the acquisition of CSC-like
phenotypes
It has been reported that TP53INP1 is a cancer suppressor,
which is associated with an oncogenic microRNA miR-155
[22,23]. And repressing TP53INP1 signiﬁcantly enhanced the abil-
ity of the CD133 cells to initiate spheroid formation [24], but
whether silencing TP53INP1 could increase the population of
CD133+ cells is unknown. To investigate the effect of silencing
TP53INP1 on the CD133+ cancer cell population, we ﬁrstly transfec-
ted MHCC-97H cells with siRNA of TP53INP1 or negative control
(siTP53INP1 or siNC), and the suppression ratio was veriﬁed by
qRT-PCR and Western blot (Fig. 5A). Flow cytometric analysis
showed that knocked-down of TP53INP1 can increased CD133+
and CD90+ cells (Fig. 5C). To further indicate the role of TP53INP1
on CSC phenotype, we determined the expression of CD90, CD133
and Oct4 in siTP53INP1 and siNC cells used qPCR. The result
showed that the mRNA level of CD90, CD133 and Oct4 was signif-
icantly increased in siTP53INP1 cells compared to the siNC cells
(Fig. 5B). These results suggest that the down-regulation of
TP53INP1 could promote acquisition of CSC-like phenotypes.
3.5. MiR-155 regulate CSC phenotype through targeting TP53INP1
Our results showed that down-regulation of miR-155 could
increase the protein expression of TP53INP1 and forced re-expres-
sion of miR-155 yielded an opposing effect (Fig. 6A). Additionally,
the expression of TP53INP1 was signiﬁcantly down-regulated in-155 cells. (A) miR-155 expression was up-regulated in anti-miR-155 cells after
qPCR. (B) Flow cytometry analysis showed the increase of CD90+ and CD133+ cells
els of CD90, CD133 and Oct4 in anti-miR-155-agomir and anti-miR-155-NC cells. (D)
ti-miR-155-NC cells. Scale bar: 200 lm, ⁄P < 0.05.
Fig. 4. Overexpression of miR-155 increased CD90, CD133 and Oct4 expression. (A) The levels of miR-155 in MHCC-97H and HepG2 cells transfected with miR-155 agomir or
NC were analyzed by qPCR. (B) The levels of TP53INP1 protein in MHCC-97H and HepG2 cells transfected with miR-155 agomir or NC were analyzed by Western blotting. The
expression of stem-cell markers CD90, CD133 and Oct4 in MHCC-97H and HepG2 cells transfected with miR-155 agomir or NC (C) and (D), ⁄P < 0.05.
Fig. 5. The roles of TP53INP1 on stem-like cell phenotypes. (A) The levels of
TP53INP1 mRNA or protein in MHCC-97H cells transfected with siRNA were
analyzed by qPCR and Western blotting. (B) The expression of stem-cell markers
CD90, CD133 and Oct4 in siTP53INP1 cells and siNC cells. (C) Changes in CD90+ and
CD133+ cell population after transfection with siTP53INP1 as compared with siNC,
P < 0.05, ⁄P < 0.05.
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miR-NC (Fig. 4B), which further demonstrated the results of previ-
ous studies that TP53INP1 is a target gene of miR-155. Based on the
above conclusions we concluded that miR-155 may regulate CSC
phenotype by targeting TP53INP1. To investigate whether miR-
155 exerts its function by targeting TP53INP1, we then performed
a rescue experiment. As expected, transfection of si-TP53INP1 intoanti-miR-155 MHCC-97H cells signiﬁcantly rescued miR-155-
inhibited stem markers CD90, CD133 and Oct4 expression
(Fig. 6B and C), which further suggesting that targeting TP53INP1
is a mechanism by which miR-155 exerts its function.
4. Discussion
Recent ﬁndings support the concept that cancer stem cells
(CSCs) are integral to the development and perpetuation of several
forms of human cancer [25], and accumulating evidence has dem-
onstrated the existence of cancer stem cells in liver cancer. It has
been reported that, in HCC, CSC markers include epithelial cell
adhesion molecule (EpCAM) [26], CD133 [27], CD90 [5], CD24
[28]. However, the critical step was to characterize the underlying
molecular and biological mechanisms by which these cells can
acquire their speciﬁc-phenotype.
The deregulation of miR-155 has been implicated in various
human tumors including human hepatocellular carcinoma. Never-
theless, the role of miR-155 in liver cancer CSCs phenotype remains
largely unknown. Accumulating evidence demonstrated that there
are relationships between the EMT and CSCs, through the EMT pro-
gram cells can gain CSC characteristics [29]. It has been reported
that miR-155 plays an important role in the regulation of EMT
[18]. So we hypothesized that miR-155 may also play an important
role in the CSCs-like properties in HCC cells. In the current study,
we demonstrated that miR-155 functions to promote the acquisi-
tion of stem cell phenotype. It has been reported that miR-155
expression in the CD133+/CD338+ cells (lung cancer stem cell)
was higher than that in the lung cancer A549 cells [30]. However,
in ovarian cancer-initiating cells miR-155 was reported as a sup-
pressor [31]. All these results indicated that miR-155 does play
an important role in the process of cancer stem cell generation,
but may play different roles in different tumors cells.
It has been reported that serum-free culture medium (SFM) is
increasingly used as an effective method to enrich and identify
CSCs [32,33]. Therefore, we used this method to enrich for liver
cancer stem cells. The expression of liver cancer stem cell markers,
Fig. 6. MiR-155 regulated CSC phenotype through target TP53INP1. (A) The expression levels of TP53INP1 in anti-miR-155 cells (left) or anti-miR-155 cells transfected with
miR-155 agomir (right), as determined by Western blotting. (B and C) The effect of anti-miR-155 on stem phenotype markers were partially attenuated by silencing of
TP53INP1, ⁄P < 0.05.
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spheres compared with parental cells. These results indicated that
spheres cultured in SFM containing CSCs, we used spheres as a
liver CSC model to explore the relationship between CSCs and
miR-155. We found that the expression of miR-155 in spheres
was signiﬁcantly increased compared to parental cells, which sug-
gests that miR-155 plays an important role in regulating the stem
phenotype in liver cancer cells. Next, using a lentiviral vectors
approach, we transfected MHCC-97H cells with miR-155 inhibitor
lentiviral vectors and stably silenced miR-155 in MHCC-97H cells.
We found that MHCC-97H cells stably lacking miR-155 decreased
CD90+ and CD133+ cell population, Oct4 expression and weakened
sphere-forming capacity.
It is well known that TP53INP1 is a tumor suppressor gene
[22,34], is a p53 target gene that induces cell growth arrest and
apoptosis by modulating p53 transcriptional activity. Our current
observation together with what has been reported recently sug-
gests that TP53INP1 is a direct target gene of miR-155. It has been
reported that miR-130b promotes CD133+ liver tumor-initiating
cell growth and self-renewal via TP53INP1 [24], so we concluded
that miR-155 may regulates stem phenotype by targeting
TP53INP1 in liver cancer cells. To determine the hypothesis, we
ﬁrstly knock-down TP53INP1 using siRNA. The results showed that
TP53INP1 blockage increased CD133+ and CD90+ cells, and up-reg-
ulated Oct4. Expectedly, we also observed that CD90, CD133 and
Oct4 attenuated by anti-miR-155 rescued by knockdown of
TP53INP1. Taken together, the biological effects of miR-155 on
CSCs phenotype are probably due to the repression of TP53INP1.
In conclusion, the results of this study revealed up-regulation of
miR-155 in CSCs cells and showed that miR-155 regulates the pro-
portion of CD90+ or CD133+ CSCs, the expression of stem cell-asso-
ciated gene Oct4 and the capacity of spheres-formation, which
indicated that miR-155 may play an important role in the CSCs
acquisition and self-renewal. Importantly, the function of miR-155 exerts due to down-regulation of the tumor suppressor
TP53INP1. The present study implies the intriguing possibility of
miR-155 may be used as a potential therapeutic target for the
treatment of patients with HCC.
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